Payment overview · 2025
General Payments
$2,111.67
77 reported records · 18 companies
Healthcare provider profile · identity verified
Ali Khusseyn, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1396792594
Verified facts
What the public records show
CMS Open Payments records show Ali Khusseyn, M.D. received $2,111.67 in general payments during 2025 across 77 reported records.
ABBVIE INC. accounted for 23.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Trelegy Ellipta, Ubrelvy, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 195 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBI as an associated drug or biological on 1140 records involving 805 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Edarbi by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Edarbyclor by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $501.35 | 23.7% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $392.93 | 18.6% | 11 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $346.24 | 16.4% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $155.38 | 7.4% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $106.95 | 5.1% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $103.43 | 4.9% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $91.91 | 4.3% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$80.51 | 3.8% | 3 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.31 | 3.6% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $56.26 | 2.7% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $44.76 | 2.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.84 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.13 | 1.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.39 | 1.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.99 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.54 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.18 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.57 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,111.67 | 77 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $451.89 | 14 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $346.24 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $241.09 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $125.34 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $118.71 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $116.96 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $103.43 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $91.91 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $83.00 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $80.51 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $56.26 | 2 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $53.54 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $51.55 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $47.99 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $44.76 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $36.67 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.84 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 126 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 100 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 226 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
126 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
226 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
195 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
155 | 25 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
100 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBI open payments reported associated product |
CMS Open Payments — General Payments 1140 supporting records · 805 recipient NPIs · example record 1242666830 |
Edarbi · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 624 | 95 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 456 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 70 |
| Losartan Potassium | Losartan Potassium | 380 | 69 |
| Omeprazole | Omeprazole | 361 | 52 |
| Diclofenac Sodium | Diclofenac Sodium | 330 | 51 |
| Metformin Hcl | Metformin Hcl | 304 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 260 | 39 |
| Eliquis | Apixaban | 258 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 246 | 31 |
| Linzess | Linaclotide | 226 | 35 |
| Gabapentin | Gabapentin | 219 | 35 |
| Vascepa | Icosapent Ethyl | 210 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 207 | 34 |
| Synthroid | Levothyroxine Sodium | 195 | 21 |
| Memantine Hcl | Memantine Hcl | 192 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 177 | 26 |
| Nifedipine Er | Nifedipine | 157 | 21 |
| Zenpep | Lipase/Protease/Amylase | 155 | 25 |
| Icosapent Ethyl | Icosapent Ethyl | 147 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 147 | 22 |
| Furosemide | Furosemide | 146 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 21 |
| Ezetimibe | Ezetimibe | 127 | 20 |
| Creon | Lipase/Protease/Amylase | 126 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 21 |
| Allopurinol | Allopurinol | 124 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 124 | 21 |
| Carvedilol | Carvedilol | 123 | 18 |
| Atenolol | Atenolol | 120 | 12 |
| Simvastatin | Simvastatin | 109 | 15 |
| Famotidine | Famotidine | 108 | 17 |
| Jardiance | Empagliflozin | 106 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 104 | 13 |
| Januvia | Sitagliptin Phosphate | 102 | 13 |
| Farxiga | Dapagliflozin Propanediol | 100 | 14 |
| Tradjenta | Linagliptin | 97 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 12 |
| Glimepiride | Glimepiride | 84 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 17 |
| Lidocaine | Lidocaine | 80 | 12 |
| Ibuprofen | Ibuprofen | 78 | 27 |
| Donepezil Hcl | Donepezil Hcl | 74 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 73 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 28 |
| Celecoxib | Celecoxib | 71 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 71 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 68 | 18 |
| Finasteride | Finasteride | 67 | 12 |
| Crestor | Rosuvastatin Calcium | 65 | suppressed |
| Dutasteride | Dutasteride | 65 | suppressed |
| Potassium Chloride | Potassium Chloride | 65 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | suppressed |
| Entresto | Sacubitril/Valsartan | 62 | suppressed |
| Ranolazine Er | Ranolazine | 62 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 61 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 12 |
| Clotrimazole | Clotrimazole | 59 | 18 |
| Memantine Hcl Er | Memantine Hcl | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 57 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 54 | suppressed |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 50 | suppressed |
| Chlorthalidone | Chlorthalidone | 49 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Loperamide | Loperamide Hcl | 47 | 12 |
| Meclizine Hcl | Meclizine Hcl | 47 | 22 |
| Dexilant | Dexlansoprazole | 46 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 46 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Edarbi | Azilsartan Medoxomil | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 41 | suppressed |
| Lisinopril | Lisinopril | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Telmisartan | Telmisartan | 36 | suppressed |
| Azithromycin | Azithromycin | 35 | 29 |
| Baclofen | Baclofen | 35 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | 11 |
| Procto-Med Hc | Hydrocortisone | 33 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 32 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Norvasc | Amlodipine Besylate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 15 |
| Lyrica | Pregabalin | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | 11 |
| Prednisone | Prednisone | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Prolia | Denosumab | 20 | 11 |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Benicar | Olmesartan Medoxomil | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Avalide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 13 |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Avapro | Irbesartan | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Singulair | Montelukast Sodium | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Ambien Cr | Zolpidem Tartrate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Zovirax | Acyclovir | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Felodipine Er | Felodipine | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,111.67 · 77 records | ABBVIE INC. | ALVESCO, AUSTEDO XR, Auvelity, CREON, CREXONT, FARXIGA, HORIZANT, IBSRELA, INGREZZA, KISUNLA, LINZESS, Leqembi, NUPLAZID, PONVORY, QULIPTA, REPATHA, REXULTI, Symbravo, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VRAYLAR, VYEPTI, ZENPEP | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error